Effects of artemisinin and cisplatin on the malignant progression of oral leukoplakia. In vitro and in vivo study.

OBJECTIVES: Chemoprevention can be a treatment for potentially malignant lesions (PMLs). We aimed to evaluate whether artemisinin (ART) and cisplatin (CSP) are associated with apoptosis and immunogenic cell death (ICD) in vitro, using oral leukoplakia (OL) and oral squamous cell carcinoma (OSCC) cell lines, and whether these compounds prevent OL progression in vivo. METHODS: Normal keratinocytes (HaCat), Dysplastic oral cells (DOK), and oral squamous cell carcinoma (SCC-180) cell lines were treated with ART, CSP, and ART + CSP to analyze cytotoxicity, genotoxicity, cell migration, and increased expression of proteins related to apoptosis and ICD. Additionally, 41 mice were induced with OL using 4NQO, treated with ART and CSP, and their tongues were histologically analyzed. RESULTS: In vitro, CSP and CSP + ART showed dose-dependent cytotoxicity and reduced SCC-180 migration. No treatment was genotoxic, and none induced expression of proteins related to apoptosis and ICD; CSP considerably reduced High-mobility group box-1 (HMGB-1) protein expression in SCC-180. In vivo, there was a delay in OL progression with ART and CSP treatment; however, by the 16th week, only CSP prevented progression to OSCC. CONCLUSION: Expression of proteins related to ICD and apoptosis did not increase with treatments, and CSP was shown to reduce immunogenic pathways in SCC-180, while reducing cell migration. ART did not prevent the malignant progression of OL in vivo; CSP did despite significant adverse effects.

Artemisinin: An Anti-Leishmania Drug that Targets the Leishmania Parasite and Activates Apoptosis of Infected Cells.

Leishmaniasis is a relevant disease worldwide due to its presence in many countries and an estimated prevalence of 10 million people. The causative agent of this disease is the obligate intracellular parasite Leishmania which can infect different cell types. Part of its success depends on its ability to evade host defense mechanisms such as apoptosis. Apoptosis is a finely programmed process of cell death in which cells silently dismantle and actively participate in several processes such as immune response, differentiation, and cell growth. Leishmania has the ability to delay its initiation to persist in the cell. It has been well documented that different Leishmania species target different pathways that lead to apoptosis of cells such as macrophages, neutrophils, and dendritic cells. In many cases, the observed anti-apoptotic effect has been associated with a significant reduction in caspase-3 activity. Leishmania has also been shown to target several pathways involved in apoptosis such as MAPK, PI3K/Akt, and the antiapoptotic protein Bcl-xL. Understanding the strategies used by Leishmania to subvert the defense mechanisms of host cells, particularly apoptosis, is very relevant for the development of therapies and vaccines. In recent years, the drug artemisinin has been shown to be effective against several parasitic diseases. Its role against Leishmania may be promising. In this review, we provide important aspects of the disease, the strategies used by the parasite to suppress apoptosis, and the role of artemisinin in Leishmania infection.

Temporal and spatial dynamics of Plasmodium falciparum clonal lineages in Guyana.

Plasmodium parasites, the causal agents of malaria, are eukaryotic organisms that obligately undergo sexual recombination within mosquitoes. In low transmission settings, parasites recombine with themselves, and the clonal lineage is propagated rather than broken up by outcrossing. We investigated whether stochastic/neutral factors drive the persistence and abundance of Plasmodium falciparum clonal lineages in Guyana, a country with relatively low malaria transmission, but the only setting in the Americas in which an important artemisinin resistance mutation (pfk13 C580Y) has been observed. We performed whole genome sequencing on 1,727 Plasmodium falciparum samples collected from infected patients across a five-year period (2016-2021). We characterized the relatedness between each pair of monoclonal infections (n = 1,409) through estimation of identity-by-descent (IBD) and also typed each sample for known or candidate drug resistance mutations. A total of 160 multi-isolate clones (mean IBD ≥ 0.90) were circulating in Guyana during the study period, comprising 13 highly related clusters (mean IBD ≥ 0.40). In the five-year study period, we observed a decrease in frequency of a mutation associated with artemisinin partner drug (piperaquine) resistance (pfcrt C350R) and limited co-occurence of pfcrt C350R with duplications of plasmepsin 2/3, an epistatic interaction associated with piperaquine resistance. We additionally observed 61 nonsynonymous substitutions that increased markedly in frequency over the study period as well as a novel pfk13 mutation (G718S). However, P. falciparum clonal dynamics in Guyana appear to be largely driven by stochastic factors, in contrast to other geographic regions, given that clones carrying drug resistance polymorphisms do not demonstrate enhanced persistence or higher abundance than clones carrying polymorphisms of comparable frequency that are unrelated to resistance. The use of multiple artemisinin combination therapies in Guyana may have contributed to the disappearance of the pfk13 C580Y mutation.

The human malaria-Aotus monkey model: a historical perspective in antimalarial chemotherapy research at the Gorgas Memorial Laboratory-Panama.

The human malaria-Aotus monkey model has served the malaria research community since its inception in 1966 at the Gorgas Memorial Laboratory (GML) in Panama. Spanning over five decades, this model has been instrumental in evaluating the in vivo efficacy and pharmacokinetics of a wide array of candidate antimalarial drugs, whether used singly or in combination. The animal model could be infected with drug-resistant and susceptible Plasmodium falciparum and Plasmodium vivax strains that follow a characteristic and reproducible course of infection, remarkably like human untreated and treated infections. Over the years, the model has enabled the evaluation of several synthetic and semisynthetic endoperoxides, for instance, artelinic acid, artesunate, artemether, arteether, and artemisone. These compounds have been evaluated alone and in combination with long-acting partner drugs, commonly referred to as artemisinin-based combination therapies, which are recommended as first-line treatment against uncomplicated malaria. Further, the model has also supported the evaluation of the primaquine analog tafenoquine against blood stages of P. vivax, contributing to its progression to clinical trials and eventual approval. Besides, the P. falciparum/Aotus model at GML has also played a pivotal role in exploring the biology, immunology, and pathogenesis of malaria and in the characterization of drug-resistant P. falciparum and P. vivax strains. This minireview offers a historical overview of the most significant contributions made by the Panamanian owl monkey (Aotus lemurinus lemurinus) to malaria chemotherapy research.

Characterization of antimalarial activity of artemisinin-based hybrid drugs.

In response to the spread of artemisinin (ART) resistance, ART-based hybrid drugs were developed, and their activity profile was characterized against drug-sensitive and drug-resistant Plasmodium falciparum parasites. Two hybrids were found to display parasite growth reduction, stage-specificity, speed of activity, additivity of activity in drug combinations, and stability in hepatic microsomes of similar levels to those displayed by dihydroartemisinin (DHA). Conversely, the rate of chemical homolysis of the peroxide bonds is slower in hybrids than in DHA. From a mechanistic perspective, heme plays a central role in the chemical homolysis of peroxide, inhibiting heme detoxification and disrupting parasite heme redox homeostasis. The hybrid exhibiting slow homolysis of peroxide bonds was more potent in reducing the viability of ART-resistant parasites in a ring-stage survival assay than the hybrid exhibiting fast homolysis. However, both hybrids showed limited activity against ART-induced quiescent parasites in the quiescent-stage survival assay. Our findings are consistent with previous results showing that slow homolysis of peroxide-containing drugs may retain activity against proliferating ART-resistant parasites. However, our data suggest that this property does not overcome the limited activity of peroxides in killing non-proliferating parasites in a quiescent state.

Molecular Surveillance of Artemisinin-Resistant Plasmodium falciparum Parasites in Mining Areas of the Roraima Indigenous Territory in Brazil.

Multidrug- and artemisinin-resistant (ART-R) Plasmodium falciparum (Pf) parasites represent a challenge for malaria elimination worldwide. Molecular monitoring in the Kelch domain region (pfk13) gene allows tracking mutations in parasite resistance to artemisinin. The increase in illegal miners in the Roraima Yanomami indigenous land (YIL) could favor ART-R parasites. Thus, this study aimed to investigate ART-R in patients from illegal gold mining areas in the YIL of Roraima, Brazil. A questionnaire was conducted, and blood was collected from 48 patients diagnosed with P. falciparum or mixed malaria (Pf + P. vivax). The DNA was extracted and the pfk13 gene was amplified by PCR. The amplicons were subjected to DNA-Sanger-sequencing and the entire amplified fragment was analyzed. Among the patients, 96% (46) were from illegal mining areas of the YIL. All parasite samples carried the wild-type genotypes/ART-sensitive phenotypes. These data reinforce the continued use of artemisinin-based combination therapies (ACTs) in Roraima, as well as the maintenance of systematic monitoring for early detection of parasite populations resistant to ART, mainly in regions with an intense flow of individuals from mining areas, such as the YIL. This is especially true when the achievement of falciparum malaria elimination in Brazil is planned and expected by 2030.

Kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity during Plasmodium vivax infection: implications for early radical malaria treatment.

BACKGROUND: Plasmodium vivax relapses due to dormant liver hypnozoites can be prevented with primaquine. However, the dose must be adjusted in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. In French Guiana, assessment of G6PD activity is typically delayed until day (D)14 to avoid the risk if misclassification. This study assessed the kinetics of G6PD activity throughout P. vivax infection to inform the timing of treatment. METHODS: For this retrospective monocentric study, data on G6PD activity between D1 and D28 after treatment initiation with chloroquine or artemisinin-based combination therapy were collected for patients followed at Cayenne Hospital, French Guiana, between January 2018 and December 2020. Patients were divided into three groups based on the number of available G6PD activity assessments: (i) at least two measurements during the P. vivax malaria infection; (ii) two measurements: one during the current infection and one previously; (iii) only one measurement during the malaria infection. RESULTS: In total, 210 patients were included (80, 20 and 110 in groups 1, 2 and 3, respectively). Data from group 1 showed that G6PD activity remained stable in each patient over time (D1, D3, D7, D14, D21, D28). None of the patients with normal G6PD activity during the initial phase (D1-D3) of the malaria episode (n = 44) was categorized as G6PD-deficient at D14. Patients with G6PD activity < 80% at D1 or D3 showed normal activity at D14. Sex and reticulocyte count were statistically associated with G6PD activity variation. In the whole sample (n = 210), no patient had severe G6PD deficiency (< 10%) and only three between 10 and 30%, giving a G6PD deficiency prevalence of 1.4%. Among the 100 patients from group 1 and 2, 30 patients (26.5%) were lost to follow-up before primaquine initiation. CONCLUSIONS: In patients treated for P. vivax infection, G6PD activity did not vary over time. Therefore, G6PD activity on D1 instead of D14 could be used for primaquine dose-adjustment. This could allow earlier radical treatment with primaquine, that could have a public health impact by decreasing early recurrences and patients lost to follow-up before primaquine initiation. This hypothesis needs to be confirmed in larger prospective studies.

Delayed gametocyte clearance in Plasmodium vivax malaria is associated with polymorphisms in the cytochrome P450 reductase (CPR).

Primaquine (PQ) is the main drug used to eliminate dormant liver stages and prevent relapses in Plasmodium vivax malaria. It also has an effect on the gametocytes of Plasmodium falciparum; however, it is unclear to what extent PQ affects P. vivax gametocytes. PQ metabolism involves multiple enzymes, including the highly polymorphic CYP2D6 and the cytochrome P450 reductase (CPR). Since genetic variability can impact drug metabolism, we conducted an evaluation of the effect of CYP2D6 and CPR variants on PQ gametocytocidal activity in 100 subjects with P. vivax malaria. To determine gametocyte density, we measured the levels of pvs25 transcripts in samples taken before treatment (D0) and 72 hours after treatment (D3). Generalized estimating equations (GEEs) were used to examine the effects of enzyme variants on gametocyte densities, adjusting for potential confounding factors. Linear regression models were adjusted to explore the predictors of PQ blood levels measured on D3. Individuals with the CPR mutation showed a smaller decrease in gametocyte transcript levels on D3 compared to those without the mutation (P = 0.02, by GEE). Consistent with this, higher PQ blood levels on D3 were associated with a lower reduction in pvs25 transcripts. Based on our findings, the CPR variant plays a role in the persistence of gametocyte density in P. vivax malaria. Conceptually, our work points to pharmacogenetics as a non-negligible factor to define potential host reservoirs with the propensity to contribute to transmission in the first days of CQ-PQ treatment, particularly in settings and seasons of high Anopheles human-biting rates.

Brazilian plants with antimalarial activity: A review of the period from 2011 to 2022.

ETHNOPHARMACOLOGICAL RELEVANCE: Malaria continues to be a serious global public health problem in subtropical and tropical countries of the world. The main drugs used in the treatment of human malaria, quinine and artemisinin, are isolates of medicinal plants, making the use of plants a widespread practice in countries where malaria is endemic. Over the years, due to the increased resistance of the parasite to chloroquine and artemisinin in certain regions, new strategies for combating malaria have been employed, including research with medicinal plants. AIM: This review focuses on the scientific production regarding medicinal plants from Brazil whose antimalarial activity was evaluated during the period from 2011 to 2022. 2. METHODOLOGY: For this review, four electronic databases were selected for research: Pubmed, ScienceDirect, Scielo and Periódicos CAPES. Searches were made for full texts published in the form of scientific articles written in Portuguese or English and in a digital format. In addition, prospects for new treatments as well as future research that encourages the search for natural products and antimalarial derivatives are also presented. RESULTS: A total of 61 publications were encountered, which cited 36 botanical families and 92 species using different Plasmodium strains in in vitro and in vivo assays. The botanical families with the most expressive number of species found were Rubiaceae, Apocynaceae, Fabaceae and Asteraceae (14, 14, 9 and 6 species, respectively), and the most frequently cited species were of the genera Psychotria L. (8) and Aspidosperma Mart. (12), which belong to the families Rubiaceae and Apocynaceae. Altogether, 75 compounds were identified or isolated from 28 different species, 31 of which are alkaloids. In addition, the extracts of the analyzed species, including the isolated compounds, showed a significant reduction of parasitemia in P. falciparum and P. berghei, especially in the clones W2 CQ-R (in vitro) and ANKA (in vivo), respectively. The Brazilian regions with the highest number of species analyzed were those of the north, especially the states of Pará and Amazonas, and the southeast, especially the state of Minas Gerais. CONCLUSION: Although many plant species with antimalarial potential have been identified in Brazil, studies of new antimalarial molecules are slow and have not evolved to the production of a phytotherapeutic medicine. Given this, investigations of plants of traditional use and biotechnological approaches are necessary for the discovery of natural antimalarial products that contribute to the treatment of the disease in the country and in other endemic regions.

Evaluation of the ovicidal activity and fasciolicidal activity of the extract of ethyl acetate from Artemisia ludoviciana Nutt. spp. mexicana and of artemisinin against adult parasites of Fasciola hepatica.

The objective of this work was to evaluate the effect of the ethyl acetate extract from A. ludoviciana (EALM) and artemisinin against adult parasites and eggs of F. hepatica. For the ovicidal assay, cell culture plates with 24 wells were used, and 90 to 110 F. hepatica eggs were placed in each well. The eggs were exposed to concentrations of 100, 200, 300, 400, and 500 mg/L EALM and incubated for 16 days. Additionally, triclabendazole (TCBZ) was used as a reference drug at concentrations of 10 and 50 mg, and the response of artemisinin at concentrations of 10 and 20 mg was simultaneously assessed. Adult flukes were exposed to concentrations of 125, 250, 375, and 500 mg/L EALM. The results of the ovicidal action of EALM on the eggs showed that concentrations greater than 300 mg/L were significant, with ovicidal percentages greater than 60% observed on day 16 of incubation (p < 0.05). The maximum efficiency of EALM on adult flukes was reached 72 h post-exposure at a concentration of 125 mg/L (p < 0.05).

Molecular characterization of the Plasmodium falciparum k13 gene helix domain in samples from native communities of Condorcanqui, Amazonas, Perú / Caracterización molecular del dominio de la hélice del gen k13 de Plasmodium falciparum en muestras de comunidades nativas de Condorcanqui, Amazonas, Perú.

Introduction. Resistance of Plasmodium falciparum to different antimalarial drugs is an obstacle to disease elimination. The artemisinin-resistant genotype of P. falciparum can be assessed by examining polymorphisms in the helix domain of the Pfk13 gene. The World Health Organization recommends these mutations as molecular markers to detect artemisinin-resistant in countries where P. falciparum malaria is endemic. Objective. To identify artemisinin resistance-related mutations present in the helix domain of the P. falciparum k13 gene. Materials and methods. We collected a total of 51 samples through passive case detection, positive for Plasmodium by microscopy, from six communities in the district of Río Santiago in Condorcanqui, Amazonas. Molecular species confirmation was performed by real-time PCR and Pfk13 helix domain was amplified and sequenced by capillary electrophoresis. The obtained sequences were compared with the wild type 3D7 reference strain. Results. A total of 51 positive samples were confirmed for P. falciparum from the communities of Ayambis, Chapiza, Palometa, Muchinguis, Alianza Progreso and Caterpiza. DNA sequences alignment showed the absence of resistance-associated mutations in the k13 gene of the collected samples. Discussion. The obtained results are consistent with similar studies conducted in other South American countries, including Perú, so these data provide a baseline for artemisinin-resistance molecular surveillance in the Amazon region and reinforce the efficacy of artemisinin-based combination therapy in this area.

Introducción. La resistencia de Plasmodium falciparum a diferentes fármacos antipalúdicos es un obstáculo para eliminar la enfermedad. El genotipo resistente de P. falciparum a la artemisinina puede evaluarse examinando los polimorfismos en el dominio de la hélice del gen Pfk13. La Organización Mundial de la Salud recomienda utilizar estas mutaciones como marcadores moleculares para detectar la resistencia a la artemisinina en países donde la malaria por P. falciparum es endémica. Objetivo. Identificar mutaciones relacionadas con la resistencia a artemisinina presentes en el dominio de la hélice del gen k13 de P. falciparum. Materiales y métodos. Mediante la detección pasiva de casos, se recolectaron 51 muestras positivas por microscopía para Plasmodium, provenientes de seis comunidades del distrito de Río Santiago en Condorcanqui, Amazonas. Se realizó la confirmación molecular de la especie mediante PCR en tiempo real y el dominio de la hélice del gen Pfk13 se amplificó y secuenció por electroforesis capilar. Las secuencias obtenidas se compararon con la cepa de referencia 3D7 de fenotipo silvestre. Resultados. Se confirmó un total de 51 muestras positivas para P. falciparum, provenientes de las comunidades de Ayambis, Chapiza, Palometa, Muchinguis, Alianza Progreso y Caterpiza. Después del alineamiento de las secuencias de ADN, se determinó que las muestras no presentaron mutaciones asociadas con resistencia en el gen K13. Discusión. Los resultados obtenidos son coherentes con estudios similares realizados en otros países de Sudamérica, incluyendo Perú. Estos datos proporcionan una línea base para la vigilancia molecular de resistencia a artemisinina en la región Amazonas y refuerzan la eficacia de la terapia combinada con artemisinina en esta área.

Intravenous whole blood transfusion results in faster recovery of vascular integrity and increased survival in experimental cerebral malaria.

BACKGROUND: Cerebral malaria is a lethal complication of Plasmodium falciparum infections in need of better therapies. Previous work in murine experimental cerebral malaria (ECM) indicated that the combination of artemether plus intraperitoneal whole blood improved vascular integrity and increased survival compared to artemether alone. However, the effects of blood or plasma transfusion administered via the intravenous route have not previously been evaluated in ECM. OBJECTIVES: To evaluate the effects of intravenous whole blood compared to intravenous plasma on hematological parameters, vascular integrity, and survival in artemether-treated ECM. METHODS: Mice with late-stage ECM received artemether alone or in combination with whole blood or plasma administered via the jugular vein. The outcome measures were hematocrit and platelets; plasma angiopoietin 1, angiopoietin 2, and haptoglobin; blood-brain barrier permeability; and survival. FINDINGS: Survival increased from 54% with artemether alone to 90% with the combination of artemether and intravenous whole blood. Intravenous plasma lowered survival to 18%. Intravenous transfusion provided fast and pronounced recoveries of hematocrit, platelets, angiopoietins levels and blood brain barrier integrity. MAIN CONCLUSIONS: The outcome of artemether-treated ECM was improved by intravenous whole blood but worsened by intravenous plasma. Compared to prior studies of transfusion via the intraperitoneal route, intravenous administration was more efficacious.

Drug resistance and population structure of Plasmodium falciparum and Plasmodium vivax in the Peruvian Amazon.

Malaria is a major health problem in Peru despite substantial progress achieved by the ongoing malaria elimination program. This study explored the population genetics of 63 Plasmodium falciparum and 170 P. vivax cases collected in the Peruvian Amazon Basin between 2015 and 2019. Microscopy and PCR were used for malaria detection and positive samples were genotyped at neutral and drug resistance-associated regions. The P. falciparum population exhibited a low nucleotide diversity (π = 0.02) whereas the P. vivax population presented a higher genetic diversity (π = 0.34). All P. falciparum samples (n = 63) carried chloroquine (CQ) resistant mutations on Pfcrt. Most P. falciparum samples (53 out of 54) carried sulfadoxine (SD) resistant mutations on Pfdhfr and Pfdhps. No evidence was found of artemisinin resistance mutations on kelch13. Population structure showed that a single cluster accounted for 93.4% of the P. falciparum samples whereas three clusters were found for P. vivax. Our study shows a low genetic diversity for both species with significant differences in genetic sub-structuring. The high prevalence of CQ-resistance mutations could be a result of indirect selection pressures driven by the P. vivax treatment scheme. These results could be useful for public health authorities to safeguard the progress that Peru has achieved towards malaria elimination.

Derivados de artemisinina para el tratamiento de malaria (Plasmodium falciparum) en gestantes en el 1er, 2ndo y 3er trimestre de gestación / Artemisinin derivatives for the treatment of malaria (Plasmodium falciparum) in pregnant women in the 1st, 2nd and 3rd years trimester of pregnancy

INTRODUCCIÓN: Este documento técnico se realiza a solicitud de la Estrategia sanitaria nacional de prevención y control de enfermedades metaxénicas y otras transmitidas por vectores. a. Cuadro clínico: La malaria es una enfermedad infecciosa causada por protozoos del género Plasmodium spp. Se estima que, globalmente, la infección por Plasmodium falciparum representa más del 90% de la mortalidad por malaria. Algunos grupos corren un riesgo considerablemente mayor que la población general de contraer la malaria y presentar un cuadro clínico grave, incluidas las mujeres gestantes. La malaria en este grupo tiene efectos severos tanto en la salud maternal como en la salud del naciente, y existen probabilidades más altas de desarrollar malaria severa especialmente en el segundo y tercer trimestre de gestación. b. Tecnología sanitária: El mejor tratamiento existente, en especial para la malaria causada por P. falciparum, es el tratamiento combinado con artemisinina (TCA), que tiene por principal objetivo lograr una rápida y completa eliminación de los parásitos para evitar que un caso sin complicaciones derive en una forma grave o mortal de la enfermedad. Actualmente, la OMS recomienda el uso de TCAs para el tratamiento de la malaria por P. falciparum sin complicaciones en niños y adultos (incluidas gestantes en el segundo y tercer trimestre), y el uso de quinina-clindamicina en gestantes en el primer trimestre de gestación. Los TCAs solo se recomiendan en gestantes en el primer trimestre si la quinina-clindamicina no está disponible o hay una falla del tratamiento. Esto es debido a que el primer trimestre es el momento de mayor preocupación por posible teratogenicidad. Aun así, la evidencia con respecto a la seguridad, eficacia y farmacocinética de la mayoría de los medicamentos antipalúdicos en gestantes es limitado. OBJETIVO El objetivo del presente documento es evaluar la eficacia y seguridad, así como documentos relacionados a la decisión del uso de los derivados de la artemisinina para el tratamiento de la malaria por P. falciparum en gestantes en el primer, segundo y tercer trimestre de gestación. METODOLOGÍA Se realizó una búsqueda en las principales bases de datos bibliográficas: MEDLINE, LILACS, COCHRANE, así como en buscadores genéricos de Internet incluyendo Google Scholar y TRIPDATABASE. Adicionalmente, se hizo una búsqueda dentro de la información generada por las principales instituciones internacionales de infectología, y agencias de tecnologías sanitarias que realizan revisiones sistemáticas (RS), evaluación de tecnologías sanitarias (ETS) y guías de práctica clínica (GPC). RESULTADOS: Se seleccionaron cuatro metaanálisis, una revisión sistemática (RS), tres ECAs y cuatro guías de práctica clínica (GPC). Saito et al. publicaron dos metaanálisis con datos de pacientes individuales en 2020. El primer metaanálisis comparaba la eficacia y tolerabilidad de los derivados de la artemisinina y quinina como tratamientos para la malaria causada por P. falciparum no complicada en gestantes. Con datos derivados de 19 estudios realizados en África sub-Sahariana y Asia, se compararon un total de diez medicamentos antipalúdicos. El análisis encontró que la eficacia de los TCAs y quinina-clindamicina (QC) fue mayor del 90% en el día 28, 42 y 63 del tratamiento, mientras que la monoterapia con quinina tuvo la eficacia más baja en el día 28. El riesgo de falla de tratamiento comparado con el tratamiento estándar de artemisina-lumefantrina (AL) fue ligeramente menor para el tratamiento con artesunato-amodiaquina (ASAQ) y artesunato-mefloquina (ASMQ), y mayor para la monoterapia con quinina. En cuanto a la tolerabilidad, el tratamiento con AL tuvo el menor riesgo de eventos adversos, parecido al de la monoterapia con artesunato, y seguido de dihidroartemisinina-piperaquina (DP). Los tratamientos con quinina, ASAQ y ASMQ estuvieron asociados a un mayor riesgo de eventos adversos. El segundo metaanálisis publicado por Saito et al. comparaba los resultados del embarazo y riesgo de malaria placentaria después del tratamiento con derivados de la artemisinina y quinina para la malaria causada por P. falciparum no complicada en gestantes. Se utilizaron datos derivados de 16 estudios realizados en África subSahariana y Asia. No se identificaron diferencias estadísticamente significativas en la proporción de anomalías congénitas (p=0,68), aborto espontáneo (p=0,60), nacimiento de un niño muerto, parto prematuro moderado a tardío, ni en el riesgo de tener un bebé pequeño para la edad gestacional o de la presencia de pigmento de malaria en la placenta, entre los tratamientos antipalúdicos más comunes (AL, ASAQ, ASMQ y DP) en gestantes en el segundo y tercer trimestre. Los resultados para otros tratamientos requieren una interpretación cuidadosa debido al pequeño número de mujeres incluidas en los análisis, pero en general se asociaron con riesgos similares al tratamiento con AL. En 2017, Dellicour et al. publicaron un metaanálisis de estudios observacionales que investigaban el riesgo de eventos adversos en los resultados del embarazo relacionados al uso de derivados de la artemisinina y quinina en gestantes en el primer trimestre. Se incluyeron cinco estudios realizados en África sub-Sahariana y en la frontera entre Tailandia y Myanmar. No se encontraron diferencias significativas en el riesgo de aborto espontáneo asociado al uso de TCAs comparado con quinina en el primer trimestre de gestación, en el riesgo de nacimiento de un niño muerto, ni en la combinación de ambos eventos adversos. La prevalencia de anomalías congénitas mayores también fue similar entre ambos tratamientos. Sin embargo, el riesgo de aborto espontáneo fue mayor en gestantes tratadas con quinina comparado con gestantes no tratadas con ningún antipalúdico, mientras que esta relación no se observó en gestantes tratadas con TCAs. Burger et al. realizaron una RS en 2016 para investigar los efectos del embarazo sobre la farmacocinética de TCAs para el tratamiento de malaria en gestantes. El estudio concluyó que los regímenes actuales de artesunato, lumefantrina, sulfadoxina, atovacuona y proguanil resultan en una infradosificación del fármaco en gestantes, definida como una concentración plasmática del fármaco en el día 7 del tratamiento menor de 280 ng/ml, lo que es un umbral asociado con un mayor riesgo de recrudecimiento de la malaria. A base de la evidencia de los efectos del embarazo sobre la farmacocinética y eficacia de los TCAs para el tratamiento de la malaria en gestantes, Kloprogge et al. realizaron un metaanálisis en 2018 para investigar mejoras en el actual régimen estándar de AL, el TCA más común. Los autores encontraron que la concentración venosa de lumefantrina en el día 7 de tratamiento con un régimen estándar de AL era 20,2% menor en gestantes en el segundo y tercer trimestre de gestación comparado con adultos no gestantes (p<0,001). Los autores desarrollaron un modelo farmacocinético-farmacodinámico para comparar tres regímenes de dosificación alternativos: una dosis aumentada, un tratamiento prolongado y un tratamiento intensificado. El modelo concluyó que la dosis aumentada en gestantes no resultó en concentraciones de lumefantrina equivalentes a las de la población adulta no gestante, el tratamiento intensificado resultó en concentraciones similares, y el tratamiento prolongado mostró la probabilidad más alta de alcanzar concentraciones equivalentes. CONCLUSIONES: La evidencia con respecto a la seguridad, eficacia y farmacocinética de la mayoría de los medicamentos antipalúdicos en gestantes, incluidos los TCAs, es limitada. Dos metaanálisis publicados en 2020 encontraron una alta eficacia y tolerabilidad de los TCAs más comunes en gestantes en el segundo y tercer trimestre con malaria por P. falciparum no complicada, y no se identificaron diferencias significativas en los resultados del embarazo y riesgo de malaria placentaria entre el tratamiento con TCAs y los derivados de la quinina. En cuanto al tratamiento de gestantes en el primer trimestre de gestación, la evidencia es aún más escasa, aunque un metaanálisis de estudios observacionales tampoco encontró diferencias significativas en los riesgos de eventos adversos entre el tratamiento con TCAs y los derivados de la quinina en esta población. El embarazo causa una variedad de cambios fisiológicos que pueden afectar a la farmacocinética de los medicamentos tomados en este periodo, y que pueden reducir su eficacia. Una RS concluyó que los regímenes actuales de los TCAs más comunes también resultan en una infradosificación del fármaco en gestantes. Un tratamiento prolongado de los TCAs podría resultar en concentraciones más altas en gestantes. Debido a la escasez de la evidencia en gestantes en el primer trimestre, las actuales GPCs solo recomiendan el uso de TCAs en gestantes en el segundo y tercer trimestre de gestación. La quinina-clindamicina esta recomendada para gestantes en el primer trimestre de gestación. Tampoco se recomienda la modificación de las dosis estándar en este momento.

Antiviral activity of medicinal plant-derived products against SARS-CoV-2.

This review presents information from several studies that have demonstrated the antiviral activity of extracts (Andrographis paniculata, Artemisia annua, Artemisia afra, Cannabis sativa, Curcuma longa, Echinacea purpurea, Olea europaea, Piper nigrum, and Punica granatum) and phytocompounds derived from medicinal plants (artemisinins, glycyrrhizin, and phenolic compounds) against SARS-CoV-2. A brief background of the plant products studied, the methodology used to evaluate the antiviral activity, the main findings from the research, and the possible mechanisms of action are presented. These plant products have been shown to impede the adsorption of SARS-CoV-2 to the host cell, and prevent multiplication of the virus post its entry into the host cell. In addition to antiviral activity, the plant products have also been demonstrated to exert an immunomodulatory effect by controlling the excessive release of cytokines, which is commonly associated with SARS-CoV-2 infections.

TiO2 nanoparticles and salinity stress in relation to artemisinin production and ADS and DBR2 expression in Artemisia absinthium L / Nanopartículas de TiO2 e estresse de salinidade em relação à produção de artemisinina e expressão de ADS e DBR2 em Artemisia absinthium L

Artemisia absinthium L. is an important herb that is widely cultivated in different parts of the world for its medicinal properties. The present study evaluated the effects of four concentrations of nanoparticles treatment (0, 10, 20 and 30 mg L-¹) and NaCl salinity stress (0, 50, 100 and 150 mM NaCl) and their interactions with respect to the expression of two key genes, i.e. DBR2 and ADS, in the biosynthesis pathway of artemisinin in A. absinthium. Total RNA was extracted and a relative gene expression analysis was carried out using Real-Time PCR. The amount of artemisinin was also determined by HPLC. All the experiments were performed as factorial in a completely randomized design in three replications. The results revealed that salinity stress and nanoparticles treatment and their interaction affected the expressions of these genes significantly. The highest levels of ADS gene expression were observed in the 30 mg L-¹ nanoparticles–treated plants in the presence of 150 mM salinity stress and the lowest levels in the 10 mg L-¹ nanoparticles–treated plants under 50 mM salinity stress. The maximum DBR2 gene expression was recorded in the 10 mg L-¹ nanoparticles–treated plants in the absence of salinity stress and the minimum expression in the 100 mM salinity-stressed plants in the absence of nanoparticles treatment. Moreover, the smallest amounts of artemisinin were observed in the 150 mM salinity-stressed plants in the absence of nanoparticles and the highest amounts in the 30 mg L-¹ nanoparticles–treated plants. The maximum amounts of artemisinin and ADS gene expression were reported from the plants in the same nanoparticles treatment and salinity stress [...].(AU)

Artemisia absinthium L. é uma erva importante que é amplamente cultivada em diferentes partes do mundo por suas propriedades medicinais. O presente estudo avaliou os efeitos de quatro concentrações de tratamento com nanopartículas (0, 10, 20 e 30 mg L-¹) e estresse de salinidade com NaCl (0, 50, 100 e 150 mM NaCl) e suas interações com relação à expressão de dois genes-chave, isto é, DBR2 e ADS, na via de biossíntese da artemisinina em A. absinthium. O RNA total foi extraído, e uma análise de expressão gênica relativa foi realizada usando PCR em tempo real. A quantidade de artemisinina também foi determinada por HPLC. Todos os experimentos foram realizados como fatorial, em delineamento inteiramente casualizado, em três repetições. Os resultados revelaram que o estresse por salinidade e o tratamento com nanopartículas e sua interação afetaram significativamente as expressões desses genes. Os níveis mais altos de expressão do gene ADS foram observados nas plantas tratadas com nanopartículas de 30 mg L-¹ na presença de estresse de salinidade de 150 mM, e os níveis mais baixos, nas plantas tratadas com nanopartículas de 10 mg L-¹ com estresse de salinidade de 50 mM. A expressão máxima do gene DBR2 foi registrada nas plantas tratadas com nanopartículas de 10 mg L-¹ na ausência de estresse de salinidade, e a expressão mínima, nas plantas estressadas com salinidade de 100 mM na ausência de tratamento com nanopartículas. Além disso, as menores quantidades de artemisinina foram observadas nas plantas com estresse de salinidade de 150 mM na ausência de nanopartículas, e as maiores quantidades, nas plantas tratadas com nanopartículas de 30 mg L-¹. As quantidades máximas de expressão de genes de artemisinina e ADS foram relatadas a partir das plantas no mesmo tratamento com nanopartículas e condições de estresse de salinidade. A esse respeito, a quantidade de artemisinina diminuiu pela metade nas [...],(AU)

TiO2 nanoparticles and salinity stress in relation to artemisinin production and ADS and DBR2 expression in Artemisia absinthium L / Nanopartículas de TiO2 e estresse de salinidade em relação à produção de artemisinina e expressão de ADS e DBR2 em Artemisia absinthium L

Artemisia absinthium L. is an important herb that is widely cultivated in different parts of the world for its medicinal properties. The present study evaluated the effects of four concentrations of nanoparticles treatment (0, 10, 20 and 30 mg L-¹) and NaCl salinity stress (0, 50, 100 and 150 mM NaCl) and their interactions with respect to the expression of two key genes, i.e. DBR2 and ADS, in the biosynthesis pathway of artemisinin in A. absinthium. Total RNA was extracted and a relative gene expression analysis was carried out using Real-Time PCR. The amount of artemisinin was also determined by HPLC. All the experiments were performed as factorial in a completely randomized design in three replications. The results revealed that salinity stress and nanoparticles treatment and their interaction affected the expressions of these genes significantly. The highest levels of ADS gene expression were observed in the 30 mg L-¹ nanoparticles–treated plants in the presence of 150 mM salinity stress and the lowest levels in the 10 mg L-¹ nanoparticles–treated plants under 50 mM salinity stress. The maximum DBR2 gene expression was recorded in the 10 mg L-¹ nanoparticles–treated plants in the absence of salinity stress and the minimum expression in the 100 mM salinity-stressed plants in the absence of nanoparticles treatment. Moreover, the smallest amounts of artemisinin were observed in the 150 mM salinity-stressed plants in the absence of nanoparticles and the highest amounts in the 30 mg L-¹ nanoparticles–treated plants. The maximum amounts of artemisinin and ADS gene expression were reported from the plants in the same nanoparticles treatment and salinity stress [...].

Artemisia absinthium L. é uma erva importante que é amplamente cultivada em diferentes partes do mundo por suas propriedades medicinais. O presente estudo avaliou os efeitos de quatro concentrações de tratamento com nanopartículas (0, 10, 20 e 30 mg L-¹) e estresse de salinidade com NaCl (0, 50, 100 e 150 mM NaCl) e suas interações com relação à expressão de dois genes-chave, isto é, DBR2 e ADS, na via de biossíntese da artemisinina em A. absinthium. O RNA total foi extraído, e uma análise de expressão gênica relativa foi realizada usando PCR em tempo real. A quantidade de artemisinina também foi determinada por HPLC. Todos os experimentos foram realizados como fatorial, em delineamento inteiramente casualizado, em três repetições. Os resultados revelaram que o estresse por salinidade e o tratamento com nanopartículas e sua interação afetaram significativamente as expressões desses genes. Os níveis mais altos de expressão do gene ADS foram observados nas plantas tratadas com nanopartículas de 30 mg L-¹ na presença de estresse de salinidade de 150 mM, e os níveis mais baixos, nas plantas tratadas com nanopartículas de 10 mg L-¹ com estresse de salinidade de 50 mM. A expressão máxima do gene DBR2 foi registrada nas plantas tratadas com nanopartículas de 10 mg L-¹ na ausência de estresse de salinidade, e a expressão mínima, nas plantas estressadas com salinidade de 100 mM na ausência de tratamento com nanopartículas. Além disso, as menores quantidades de artemisinina foram observadas nas plantas com estresse de salinidade de 150 mM na ausência de nanopartículas, e as maiores quantidades, nas plantas tratadas com nanopartículas de 30 mg L-¹. As quantidades máximas de expressão de genes de artemisinina e ADS foram relatadas a partir das plantas no mesmo tratamento com nanopartículas e condições de estresse de salinidade. A esse respeito, a quantidade de artemisinina diminuiu pela metade nas [...],

TiO2 nanoparticles and salinity stress in relation to artemisinin production and ADS and DBR2 expression in Artemisia absinthium L / Nanopartículas de TiO2 e estresse de salinidade em relação à produção de artemisinina e expressão de ADS e DBR2 em Artemisia absinthium L

Artemisia absinthium L. is an important herb that is widely cultivated in different parts of the world for its medicinal properties. The present study evaluated the effects of four concentrations of nanoparticles treatment (0, 10, 20 and 30 mg L-1) and NaCl salinity stress (0, 50, 100 and 150 mM NaCl) and their interactions with respect to the expression of two key genes, i.e. DBR2 and ADS, in the biosynthesis pathway of artemisinin in A. absinthium. Total RNA was extracted and a relative gene expression analysis was carried out using Real-Time PCR. The amount of artemisinin was also determined by HPLC. All the experiments were performed as factorial in a completely randomized design in three replications. The results revealed that salinity stress and nanoparticles treatment and their interaction affected the expressions of these genes significantly. The highest levels of ADS gene expression were observed in the 30 mg L-1 nanoparticles­treated plants in the presence of 150 mM salinity stress and the lowest levels in the 10 mg L-1 nanoparticles­treated plants under 50 mM salinity stress. The maximum DBR2 gene expression was recorded in the 10 mg L-1 nanoparticles­treated plants in the absence of salinity stress and the minimum expression in the 100 mM salinity-stressed plants in the absence of nanoparticles treatment. Moreover, the smallest amounts of artemisinin were observed in the 150 mM salinity-stressed plants in the absence of nanoparticles and the highest amounts in the 30 mg L-1 nanoparticles­treated plants. The maximum amounts of artemisinin and ADS gene expression were reported from the plants in the same nanoparticles treatment and salinity stress conditions. In this regard, the amount of artemisinin was decreased by half in the plants containing the highest DBR2 gene expression. Meanwhile, no significant correlation was observed between these gene expressions and the artemisinin amount in the other nanoparticles­treated plants under different levels of salinity stress. The biosynthetic pathway of secondary metabolites appears to be very complex and dose not directly dependent on these gene expressions.

Artemisia absinthium L. é uma erva importante que é amplamente cultivada em diferentes partes do mundo por suas propriedades medicinais. O presente estudo avaliou os efeitos de quatro concentrações de tratamento com nanopartículas (0, 10, 20 e 30 mg L-1) e estresse de salinidade com NaCl (0, 50, 100 e 150 mM NaCl) e suas interações com relação à expressão de dois genes-chave, isto é, DBR2 e ADS, na via de biossíntese da artemisinina em A. absinthium. O RNA total foi extraído, e uma análise de expressão gênica relativa foi realizada usando PCR em tempo real. A quantidade de artemisinina também foi determinada por HPLC. Todos os experimentos foram realizados como fatorial, em delineamento inteiramente casualizado, em três repetições. Os resultados revelaram que o estresse por salinidade e o tratamento com nanopartículas e sua interação afetaram significativamente as expressões desses genes. Os níveis mais altos de expressão do gene ADS foram observados nas plantas tratadas com nanopartículas de 30 mg L-1 na presença de estresse de salinidade de 150 mM, e os níveis mais baixos, nas plantas tratadas com nanopartículas de 10 mg L-1 com estresse de salinidade de 50 mM. A expressão máxima do gene DBR2 foi registrada nas plantas tratadas com nanopartículas de 10 mg L-1 na ausência de estresse de salinidade, e a expressão mínima, nas plantas estressadas com salinidade de 100 mM na ausência de tratamento com nanopartículas. Além disso, as menores quantidades de artemisinina foram observadas nas plantas com estresse de salinidade de 150 mM na ausência de nanopartículas, e as maiores quantidades, nas plantas tratadas com nanopartículas de 30 mg L-1. As quantidades máximas de expressão de genes de artemisinina e ADS foram relatadas a partir das plantas no mesmo tratamento com nanopartículas e condições de estresse de salinidade. A esse respeito, a quantidade de artemisinina diminuiu pela metade nas plantas que contêm a expressão gênica DBR2 mais alta. Enquanto isso, nenhuma correlação significativa foi observada entre essas expressões gênicas e a quantidade de artemisinina nas outras plantas tratadas com nanopartículas sob diferentes níveis de estresse de salinidade. A via biossintética dos metabólitos secundários parece ser muito complexa e não depende diretamente dessas expressões gênicas.

Determination of antimalarial drugs in pharmaceutical formulations and human blood by liquid chromatography: a review.

Malaria is a life-threatening disease being treated by oral medication. This is the best treatment to reduce morbidity and mortality, prevent disease progression to the most severe form, lower the transmission of the disease and hinder the appearance of strains resistant to antimalarials. According to the World Health Organization, the most common antimalarial drugs are chloroquine, primaquine, mefloquine, lumefantrine, artemether, and artesunate in single dosage forms or fixed-dose combination. Within this context, the present review aims to show the evolution of different analytical methods that have been applied to the determination of these antimalarial drugs in pharmaceutical formulations and human blood by liquid chromatography in the last 10 years, along with statistical analyses of the methods.

TiO2 nanoparticles and salinity stress in relation to artemisinin production and ADS and DBR2 expression in Artemisia absinthium L.

Artemisia absinthium L. is an important herb that is widely cultivated in different parts of the world for its medicinal properties. The present study evaluated the effects of four concentrations of nanoparticles treatment (0, 10, 20 and 30 mg L-1) and NaCl salinity stress (0, 50, 100 and 150 mM NaCl) and their interactions with respect to the expression of two key genes, i.e. DBR2 and ADS, in the biosynthesis pathway of artemisinin in A. absinthium. Total RNA was extracted and a relative gene expression analysis was carried out using Real-Time PCR. The amount of artemisinin was also determined by HPLC. All the experiments were performed as factorial in a completely randomized design in three replications. The results revealed that salinity stress and nanoparticles treatment and their interaction affected the expressions of these genes significantly. The highest levels of ADS gene expression were observed in the 30 mg L-1 nanoparticles-treated plants in the presence of 150 mM salinity stress and the lowest levels in the 10 mg L-1 nanoparticles-treated plants under 50 mM salinity stress. The maximum DBR2 gene expression was recorded in the 10 mg L-1 nanoparticles-treated plants in the absence of salinity stress and the minimum expression in the 100 mM salinity-stressed plants in the absence of nanoparticles treatment. Moreover, the smallest amounts of artemisinin were observed in the 150 mM salinity-stressed plants in the absence of nanoparticles and the highest amounts in the 30 mg L-1 nanoparticles-treated plants. The maximum amounts of artemisinin and ADS gene expression were reported from the plants in the same nanoparticles treatment and salinity stress conditions. In this regard, the amount of artemisinin was decreased by half in the plants containing the highest DBR2 gene expression. Meanwhile, no significant correlation was observed between these gene expressions and the artemisinin amount in the other nanoparticles-treated plants under different levels of salinity stress. The biosynthetic pathway of secondary metabolites appears to be very complex and dose not directly dependent on these gene expressions.